520 related articles for article (PubMed ID: 28603071)
81. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2018 Feb; 53(2):155-161. PubMed ID: 29131152
[TBL] [Abstract][Full Text] [Related]
82. Influence of laboratory procedures on postthawing cell viability and hematopoietic engraftment after autologous peripheral blood stem cell transplantation.
Belisário AR; da Costa Funes AP; Luz JR; de Almeida Costa L; Furtado MDSBS; Martins MC; Cruz NG; Pederzoli PRMP; de Andrade RK; Libânio MRIS; de Lima Prata K
Transfusion; 2021 Apr; 61(4):1202-1214. PubMed ID: 33569783
[TBL] [Abstract][Full Text] [Related]
83. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
84. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
[TBL] [Abstract][Full Text] [Related]
85. Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.
Muta T; Miyamoto T; Kamimura T; Kanda Y; Nohgawa M; Ueda Y; Iwato K; Sasaki O; Mori T; Uchida N; Iida S; Fukuda T; Atsuta Y; Sunami K
Acta Haematol; 2018; 139(1):35-44. PubMed ID: 29339642
[TBL] [Abstract][Full Text] [Related]
86. Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions.
Törlén J; Remberger M; Le Blanc K; Ljungman P; Mattsson J
Biol Blood Marrow Transplant; 2017 Apr; 23(4):677-683. PubMed ID: 28063962
[TBL] [Abstract][Full Text] [Related]
87. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
88. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Mohan M; Susanibar-Adaniya S; Buros A; Crescencio JCR; Burgess MJ; Lusardi K; Davies F; Morgan G; Vanrhee F; Zangari M; Schinke C; Thanendrarajan S; Kothari A
Transpl Infect Dis; 2019 Apr; 21(2):e13052. PubMed ID: 30689291
[TBL] [Abstract][Full Text] [Related]
89. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
Hicks C; Isaacs A; Wong R; Chong BH
Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
[TBL] [Abstract][Full Text] [Related]
90. In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study.
Sanchez L; Sylvester M; Parrondo R; Mariotti V; Eloy JA; Chang VT
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1203-1207. PubMed ID: 28286198
[TBL] [Abstract][Full Text] [Related]
91. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
[TBL] [Abstract][Full Text] [Related]
92. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
93. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
Munshi PN; Vesole DH; St Martin A; Davila O; Kumar S; Qazilbash M; Shah N; Hari PN; D'Souza A
Cancer; 2021 Nov; 127(22):4233-4239. PubMed ID: 34374445
[TBL] [Abstract][Full Text] [Related]
94. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
95. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
96. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
97. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Am J Hematol; 2008 Aug; 83(8):614-7. PubMed ID: 18429054
[TBL] [Abstract][Full Text] [Related]
98. The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation.
Martino M; Pitino A; Tripepi G; Paviglianiti A; Russo L; Cusumano G; Rossetti A; Provenzano PF; Porto G; Meliambro N; Gallo S; Porcino D; Romeo V; Gangemi T; D'Arrigo G; Imbalzano L; Console G; Gori M
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e402-e409. PubMed ID: 33288484
[TBL] [Abstract][Full Text] [Related]
99. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma.
Morabito F; Martino M; Stelitano C; Oliva E; Kropp M; Irrera G; Console G; Fujo M; Messina G; Molica S; Callea V; Iacopino P
Haematologica; 2002 Nov; 87(11):1192-9. PubMed ID: 12414350
[TBL] [Abstract][Full Text] [Related]
100. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]